A phase I/II single center, open-label, non-randomized study to evaluate intravenous injection of Tc99m tilmanocept into Kaposi's Sarcoma patients
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Tc 99m tilmanocept (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 03 Nov 2016 Status changed from planning to not yet recruiting, according to a Navidea Biopharmaceuticals media release.
- 03 Nov 2016 According to a Navidea Biopharmaceuticals media release, the study protocol has been approved by Institutional Review Board.
- 17 May 2016 According to a Navidea Biopharmaceuticals media release, this trial is expected to begin in the second half of 2016.